G

Genesis Clinical Research | Tampa, FL

Research site
(Unclaimed)
Location
2313 W Violet Street, Tampa, Florida, United States of America
Site insights

Top conditions

Kidney Diseases (9 trials)

Renal Insufficiency (6 trials)

Chronic Renal Insufficiency (6 trials)

Liver Diseases (5 trials)

Pruritus (3 trials)

Top treatments

PF-07081532
PF-07923568
PF-07321332
nalbuphine HCl
Ritonavir
KBP-5074
Dapagliflozin
Rocatinlimab
Iron
SYNB8802

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

18 of 42
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

The purpose of this study is to understand how fosmanogepix is processed in people with varying degrees of liver dysfunction.This study is seeking pa...

Active, not recruiting
Hepatic Impairment
Drug: Fosmanogepix

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide (BLV)

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qu...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: Placebo
Drug: RTA 901
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relat...

Enrolling
Hepatic Impairment
Drug: Apalutamide

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Active, not recruiting
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

The purpose of the study is to learn about the safety of PF-07817883 and how PF-07817883 is processed in the body of adult participants. These partic...

Enrolling
COVID-19
Drug: PF-07817883

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants. This st...

Enrolling
Healthy Volunteers
Moderate Hepatic Impairment
Drug: Lorlatinib

The purpose of this study is to understand how the loss of kidney function affects study medicine (PF-07923568) in the body. People with some level o...

Enrolling
Renal Impairment
Drug: Drug: PF-07923568

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the eff...

Active, not recruiting
Chronic Kidney Diseases
Drug: KBP-5074
Drug: Placebo

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe...

Active, not recruiting
Pain
Drug: VX-548

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling
Proteinuric Kidney Disease
Drug: VX-147
Drug: Placebo

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: Placebo Multiple Doses
Drug: BION-1301 Single Dose

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.

Enrolling
Proteinuria
Glomerular Disease
Drug: Placebo
Drug: ANG-3070

This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα the...

Enrolling
Rheumatoid Arthritis
Drug: TC99m-tilmanocept

Trial sponsors

Pfizer logo

Pfizer (11 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems